scholarly journals Late Displacement After Transcatheter Mitral Valve Replacement for Degenerative Mitral Valve Disease With Massive Annular Calcification

2016 ◽  
Vol 9 (15) ◽  
pp. 1633-1634 ◽  
Author(s):  
Annabelle Nguyen ◽  
Marina Urena ◽  
Dominique Himbert ◽  
Coppelia Goublaire ◽  
Eric Brochet ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Valve Replacement ◽  
Mitral Valve Replacement ◽  
Mitral Valve Disease ◽  
Valve Disease ◽  
Transcatheter Mitral Valve Replacement ◽  
Annular Calcification

scholarly journals Transcatheter Mitral Valve Replacement for Treating Native Mitral Valve Disease: Current Status

2020 ◽  
Vol 47 (4) ◽  
pp. 271-279
Author(s):  
Yan Chen ◽  
Junjie Hu ◽  
Shunqiang Wu ◽  
San Zhang ◽  
Kaiqin Wu ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Mitral Regurgitation ◽  
Valve Replacement ◽  
Mitral Valve Replacement ◽  
Mitral Valve Disease ◽  
Mitral Stenosis ◽  
Valve Disease ◽  
Technical Success Rate ◽  
Transcatheter Mitral Valve Replacement ◽  
Transapical Access

Transcatheter mitral valve replacement is increasingly being used as a treatment for high-risk patients who have native mitral valve disease; however, no comprehensive studies on its effectiveness have been reported. We therefore searched the literature for reports on patients with native mitral valve disease who underwent transcatheter access treatment. We found 40 reports, published from September 2013 through April 2017, that described the cases of 66 patients (mean age, 71 ± 12 yr; 30 women; 30 patients with mitral stenosis, 34 with mitral regurgitation, and 2 mixed) who underwent transcatheter mitral valve replacement. We documented their baseline clinical characteristics, comorbidities, diagnostic imaging results, procedural details, and postprocedural results. Access was transapical in 41 patients and transseptal in 25. The 30-day survival rate was 82.5%. The technical success rate (83.3% overall) was slightly but not significantly better in patients who had mitral regurgitation than in those who had mitral stenosis. Transapical access procedures resulted in fewer valve-in-valve implantations than did transseptal access procedures (P=0.026). These current results indicate that transcatheter mitral valve replacement is feasible in treating native mitral disease. The slightly higher technical success rate in patients who had mitral regurgitation suggests that a valve with a specific anchoring system is needed when treating mitral stenosis. Our findings indicate that transapical access is more reliable than transseptal access and that securely anchoring the valve is still challenging in transseptal access.

scholarly journals Transseptal transcatheter mitral valve replacement

2020 ◽  
Vol 25 (8) ◽  
pp. 3842
Author(s):  
V. I. Ganyukov ◽  
R. S. Tarasov ◽  
I. V. Ganyukov
Keyword(s):  
Case Report ◽  
Mitral Valve ◽  
Valve Replacement ◽  
Mitral Valve Replacement ◽  
Mitral Valve Disease ◽  
Current Data ◽  
Valve Disease ◽  
Less Invasive ◽  
Transcatheter Mitral Valve Replacement

The review presents current data transseptal transcatheter mitral valve replacement, which is becoming an alternative method of managing mitral valve disease. Despite the fact that the transapical transcatheter approach is technically simpler, the transseptal method is less invasive. It has confirmed effectiveness and is predicted to be the most promising. The review describes the relevance, indications, methodology for selecting the required endoprosthesis, stages of procedure, complications, and the postoperative follow-up of patients. The results of publications on transseptal transcatheter mitral valve replacement are analyzed. A case report is given.

The Art of SAPIEN 3 Transcatheter Mitral Valve Replacement in Valve-in-Ring and Valve-in-Mitral-Annular-Calcification Procedures

2021 ◽  
Vol 14 (20) ◽  
pp. 2195-2214
Author(s):  
Vasilis C. Babaliaros ◽  
Robert J. Lederman ◽  
Patrick T. Gleason ◽  
Jaffar M. Khan ◽  
Keshav Kohli ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Valve Replacement ◽  
Mitral Valve Replacement ◽  
Mitral Annular Calcification ◽  
Transcatheter Mitral Valve Replacement ◽  
Sapien 3 ◽  
Annular Calcification

Predictors of Left Ventricular Outflow Tract Obstruction After Transcatheter Mitral Valve Replacement in Severe Mitral Annular Calcification: An Analysis of the Transcatheter Mitral Valve Replacement in Mitral Annular Calcification Global Registry

2021 ◽  
Vol 14 (10) ◽  
Author(s):  
Abdallah El Sabbagh ◽  
Mohammed Al-Hijji ◽  
Dee Dee Wang ◽  
Mackram Eleid ◽  
Marina Urena ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Mitral Valve ◽  
Valve Replacement ◽  
Mitral Valve Replacement ◽  
Ventricular Outflow Tract ◽  
Left Ventricular ◽  
Multidetector Row Computed Tomography ◽  
Mitral Annular Calcification ◽  
Transcatheter Mitral Valve Replacement ◽  
Annular Calcification

Background: Several studies have evaluated preprocedural imaging predictors of left ventricular outflow tract obstruction (LVOTO) after transcatheter mitral valve replacement. The patient cohorts in these studies were heterogeneous and included patients with transcatheter mitral valve replacement in failed bioprostheses, annuloplasty rings, and severe mitral annular calcification (MAC). The goal of this study was to evaluate predictors of LVOTO specific to patients undergoing valve-in-MAC. Methods: This study included patients with severe MAC who underwent valve-in-MAC and had optimal quality preprocedural multidetector row computed tomography scans eligible for retrospective analysis. Baseline demographic, echocardiographic, and procedural data on these patients were collected. multidetector row computed tomography parameters were analyzed for association with LVOTO, defined as increase in mean LVOT gradient by ≥10 mm Hg with accompanying hemodynamic instability. Results: Seventy-one patients with optimal preprocedural computed tomography scans were included in this study (mean age, 72.5±13.5 years), 9 of which developed LVOTO (all female). Baseline mean LVOT area, neo-LVOT area (145.3 versus 270.9 mm 2 ; P =0.006), indexed neo-LVOT area (90.1 versus 157.4; P =0.05), and virtual transcatheter heart valve to septum distance (3.1 versus 6.9 mm; P =0.002) were lower in the LVOTO group. Expected % LVOT area reduction was higher in the latter group (58.3 versus 42.7%; P =0.008). In the univariable analysis, the baseline mean LVOT area, neo-LVOT area, indexed neo-LVOT area, and valve to septum distance were all significantly associated with LVOTO. Conclusions: The systolic mean LVOT area, neo-LVOT area, indexed neo-LVOT, expected percentage LVOT area reduction, and the valve to septum distance were associated with LVOTO after valve-in-MAC.

Sign in / Sign up

Export Citation Format

Share Document